58 Results

People

  1. Danishefsky
    Danishefsky
  2. Li
    Li
  3. Norton
    Norton
  4. Rampal
    Rampal
  5. Wu
    Wu
  6. Morris
    Morris
  7. Sawyers
    Sawyers
  8. Stockdill
    Stockdill
  9. Abida
    Abida
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (33)
  2. Solid Tumor Oncology Division (22)
  3. Sloan Kettering Institute Faculty (13)
  4. Hematologic Malignancies, Division of (12)
  5. Molecular Pharmacology and Chemistry Program Faculty (12)
  6. Center for Hematologic Malignancies (11)
  7. Breast Medicine Service (10)
  8. Genitourinary Oncology Service (9)
  9. Survivorship Research (8)
  10. GSK Faculty (7)
  1. "nitriles"
Formats
  1. Journal Article (55)
  2. Review (3)
Groups
  1. Department of Medicine (33)
  2. Solid Tumor Oncology Division (22)
  3. Sloan Kettering Institute Faculty (13)
  4. Hematologic Malignancies, Division of (12)
  5. Molecular Pharmacology and Chemistry Program Faculty (12)
  6. Center for Hematologic Malignancies (11)

More Groups

People
  1. Samuel Danishefsky (11)
  2. Xuechen Li (7)
  3. Larry Norton (4)
  4. Raajit Rampal (4)
  5. Xiangyang Wu (4)
  6. Charles Sawyers (3)

More People

Years
  1. 2025 (4)
  2. 2024 (8)
  3. 2023 (2)
  4. 2022 (6)
  5. 2021 (1)
  6. 2017 (1)

More Years

Publications
  1. Journal of the American Chemical Society (8)
  2. Clinical Cancer Research (4)
  3. Cancer Research (3)
  4. Journal of Clinical Oncology (3)
  5. Breast Cancer Research and Treatment (2)
  6. Cancer (2)

More Publications

Publishers
  1. American Chemical Society (9)
  2. Nature Publishing Group (9)
  3. American Association for Cancer Research (7)
  4. Elsevier Inc. (4)
  5. American Society of Clinical Oncology (3)
  6. Springer (3)

More Publishers

Results (58)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer progressing on enzalutamide
    Journal Article

    Abida, W.; Hahn, A. W.; Shore, N.; Agarwal, N.; Sieber, P.; Smith, M. R.; Dorff, T.; Monk, P.; Rettig, M.; Patel, R.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib
    Journal Article

    Cortes, J. E.; Rea, D.; Mauro, M. J.; Tran, D.; Wang, P.; Jadhav, K.; Yocolly, A.; Sasaki, K.
    Journal of Medical Economics (2023)

    Fulltext@MSK | Save
  • Safely prescribing nirmatrelvir and ritonavir - Avoiding drug-drug interactions
    Journal Article

    Culas, R.; Nath, S.; Nath, S.
    JAMA Internal Medicine (2023)

    Fulltext@MSK | Save
  • Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
    Review

    Harrison, C. N.; Gupta, V. K.; Gerds, A. T.; Rampal, R.; Verstovsek, S.; Talpaz, M.; Kiladjian, J. J.; Mesa, R.; Kuykendall, A. T.; Vannucchi, A. M.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: A feasibility study
    Journal Article

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Breast Cancer Research and Treatment (2022)

    Fulltext@MSK | Save
  • Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial
    Journal Article

    Brümmendorf, T. H.; Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; Clark, R. E.; le Coutre, P.; Garcia-Gutierrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; more...
    Leukemia (2022)

    Fulltext@MSK | Save
  • Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
    Journal Article

    Verstovsek, S.; Mesa, R.; Talpaz, M.; Kiladjian, J. J.; Harrison, C. N.; Oh, S. T.; Vannucchi, A. M.; Rampal, R.; Scott, B. L.; Buckley, S. A.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND)
    Journal Article

    Harrison, M. R.; Davis, P. G.; Khouri, M. G.; Bartlett, D. B.; Gupta, R. T.; Armstrong, A. J.; McNamara, M. A.; Zhang, T.; Anand, M.; Onyenwoke, K.; more...
    Prostate Cancer and Prostatic Diseases (2022)

    Fulltext@MSK | Save
  • Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: A randomized phase 3 trial
    Journal Article

    Powles, T.; Yuen, K. C.; Gillessen, S.; Kadel, E. E. 3rd; Rathkopf, D.; Matsubara, N.; Drake, C. G.; Fizazi, K.; Piulats, J. M.; Wysocki, P. J.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save